Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Complement c5 inhibitors
7 evidence topics · 8 sources
Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update
“In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance
“Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: FDA-labeled indication, dosing, and pivotal trial
Eculizumab biosimilars: FDA-labeled indication
Ravulizumab: FDA-labeled indication, dosing, and pivotal trial
Zilucoplan: FDA-labeled indication, dosing, and pivotal trial
Target of approved complement inhibitors
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote